This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Acting on the Drug Supply Chain Security Act
The US drug supply chain is not immune to counterfeits – so here’s what we can do about it
